Alan Dunton
Director/Board Member at CORMEDIX INC.
Net worth: 195 639 $ as of 2024-04-29
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
John Prendergast | M | 70 | 38 years | |
Kimberly Murphy | F | 62 | 4 years | |
Carl Spana | M | 61 | 38 years | |
Stephen Wills | M | 67 | 27 years | |
Arlene Morris | F | 72 | 17 years | |
Kazuko Matsuda | M | 58 | 14 years | |
Michele Dilizia | F | - | 12 years | |
James Graham | M | - | 12 years | |
Frederick Telling | M | 73 | 14 years | |
Myron Kaplan | M | 79 | 8 years | |
Janet Huffman | F | 52 | 1 years | |
Charles Pope | M | 73 | 14 years | |
Elizabeth Masson-Hurlburt | F | 45 | 6 years | |
Justin Ward | M | - | 8 years | |
Joseph Wolk | M | 57 | 26 years | |
Mathew David | M | 47 | 4 years | |
Robert Stewart | M | 56 | 1 years | |
Alistair McKeough | M | - | 7 years | |
Gregory Duncan | M | 59 | 4 years | |
Joseph Redmond | M | 64 | 1 years | |
Anthony Manning | M | 62 | 7 years | |
Joseph Todisco | M | 48 | 2 years | |
Janet Dillione | F | 65 | 9 years | |
Steven Lefkowitz | M | 68 | 7 years | |
Robert deVeer | M | 78 | 26 years | |
John Gandolfo | M | 63 | 1 years | |
Robert Koski | M | 65 | 15 years | |
Joseph Hull | M | 71 | 19 years | |
Bruce Cassidy | M | 74 | 1 years | |
David Wilson | M | 61 | 8 years | |
Beth Zelnick Kaufman | F | - | 1 years | |
David J. McLachlan | M | 86 |
ActivBiotics, Inc.
ActivBiotics, Inc. BiotechnologyHealth Technology ActivBiotics, Inc. discovers and develops pharmaceutical drugs. It provides discovery, development, and commercialization of therapies for the treatment of vascular disease, inflammation, and other high-value chronic and infectious diseases. The company was founded in 1996 and is headquartered in Lexington, MA. | - |
John W. Littlechild | M | 72 |
ActivBiotics, Inc.
ActivBiotics, Inc. BiotechnologyHealth Technology ActivBiotics, Inc. discovers and develops pharmaceutical drugs. It provides discovery, development, and commercialization of therapies for the treatment of vascular disease, inflammation, and other high-value chronic and infectious diseases. The company was founded in 1996 and is headquartered in Lexington, MA. | - |
Michael E. Hanson | M | 74 |
ActivBiotics, Inc.
ActivBiotics, Inc. BiotechnologyHealth Technology ActivBiotics, Inc. discovers and develops pharmaceutical drugs. It provides discovery, development, and commercialization of therapies for the treatment of vascular disease, inflammation, and other high-value chronic and infectious diseases. The company was founded in 1996 and is headquartered in Lexington, MA. | - |
Constantine E. Anagnostopoulos | M | 101 |
ActivBiotics, Inc.
ActivBiotics, Inc. BiotechnologyHealth Technology ActivBiotics, Inc. discovers and develops pharmaceutical drugs. It provides discovery, development, and commercialization of therapies for the treatment of vascular disease, inflammation, and other high-value chronic and infectious diseases. The company was founded in 1996 and is headquartered in Lexington, MA. | - |
Walter A. Gilbert | M | 92 |
ActivBiotics, Inc.
ActivBiotics, Inc. BiotechnologyHealth Technology ActivBiotics, Inc. discovers and develops pharmaceutical drugs. It provides discovery, development, and commercialization of therapies for the treatment of vascular disease, inflammation, and other high-value chronic and infectious diseases. The company was founded in 1996 and is headquartered in Lexington, MA. | - |
Stephen Slusher | M | - | - | |
Jeffrey Courtney | M | 65 |
ActivBiotics, Inc.
ActivBiotics, Inc. BiotechnologyHealth Technology ActivBiotics, Inc. discovers and develops pharmaceutical drugs. It provides discovery, development, and commercialization of therapies for the treatment of vascular disease, inflammation, and other high-value chronic and infectious diseases. The company was founded in 1996 and is headquartered in Lexington, MA. | - |
Gerry Brunk | M | 55 |
ActivBiotics, Inc.
ActivBiotics, Inc. BiotechnologyHealth Technology ActivBiotics, Inc. discovers and develops pharmaceutical drugs. It provides discovery, development, and commercialization of therapies for the treatment of vascular disease, inflammation, and other high-value chronic and infectious diseases. The company was founded in 1996 and is headquartered in Lexington, MA. | - |
Samrat Sisodia | M | - | - | |
John Dodd | M | - | - | |
Thomas Jarrett | M | - | - | |
Tushar Mukherjee | M | - | 2 years | |
George Davy | M | 72 | 23 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Bob Cook | M | 68 |
EpiCept Corp.
EpiCept Corp. Pharmaceuticals: MajorHealth Technology EpiCept Corp. is a pharmaceutical company, which focuses on the clinical development and commercialization of pharmaceutical products for the treatment of cancer and pain. The company focuses on analgesics targeting peripheral nerve receptors and cancer therapies. Its lead product Ceplene, is used concomitantly with low-dose interleukin-2, is intended as remission maintenance therapy in the treatment of acute myeloid leukemia for adult patients. The company's other oncology compounds include AmiKet, a late-stage pain product candidate for the treatment of peripheral neuropathies, and two other oncology compounds in clinical development, that that were discovered using in-house technology and have been shown to act as vascular disruption agents in solid tumors. EpiCept was founded in March 1993 and is headquartered in Tarrytown, NY. | 13 years |
Michael O'Keefe Sullivan | M | 67 | 10 years | |
Robert G. Savage | M | 70 |
EpiCept Corp.
EpiCept Corp. Pharmaceuticals: MajorHealth Technology EpiCept Corp. is a pharmaceutical company, which focuses on the clinical development and commercialization of pharmaceutical products for the treatment of cancer and pain. The company focuses on analgesics targeting peripheral nerve receptors and cancer therapies. Its lead product Ceplene, is used concomitantly with low-dose interleukin-2, is intended as remission maintenance therapy in the treatment of acute myeloid leukemia for adult patients. The company's other oncology compounds include AmiKet, a late-stage pain product candidate for the treatment of peripheral neuropathies, and two other oncology compounds in clinical development, that that were discovered using in-house technology and have been shown to act as vascular disruption agents in solid tumors. EpiCept was founded in March 1993 and is headquartered in Tarrytown, NY. | 16 years |
Tom Manion | M | 70 |
The Janssen Research Foundation
| 10 years |
Peter García | M | 62 | 2 years | |
Joseph deBethizy | M | 74 |
Targacept, Inc.
Targacept, Inc. Pharmaceuticals: OtherHealth Technology Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC. | 15 years |
Alan Musso | M | 62 |
Targacept, Inc.
Targacept, Inc. Pharmaceuticals: OtherHealth Technology Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC. | 12 years |
J. Michael French | M | 63 | 8 years | |
Steven Gilman | M | 71 |
ActivBiotics, Inc.
ActivBiotics, Inc. BiotechnologyHealth Technology ActivBiotics, Inc. discovers and develops pharmaceutical drugs. It provides discovery, development, and commercialization of therapies for the treatment of vascular disease, inflammation, and other high-value chronic and infectious diseases. The company was founded in 1996 and is headquartered in Lexington, MA. | 3 years |
Brian John Bohunicky | M | 69 | 3 years | |
Joseph W. Ramelli | M | 55 | 6 years | |
Alan F. Joslyn | M | 65 | 15 years | |
Mohammed Khoso Baluch | M | 66 | 5 years | |
Phoebe Mounts | M | 74 | 4 years | |
Paulo Costa | M | 73 | 9 years | |
Michael Taylor | M | 69 | 2 years | |
John Martin | M | 62 | 10 years | |
John V. Talley | M | 68 |
EpiCept Corp.
EpiCept Corp. Pharmaceuticals: MajorHealth Technology EpiCept Corp. is a pharmaceutical company, which focuses on the clinical development and commercialization of pharmaceutical products for the treatment of cancer and pain. The company focuses on analgesics targeting peripheral nerve receptors and cancer therapies. Its lead product Ceplene, is used concomitantly with low-dose interleukin-2, is intended as remission maintenance therapy in the treatment of acute myeloid leukemia for adult patients. The company's other oncology compounds include AmiKet, a late-stage pain product candidate for the treatment of peripheral neuropathies, and two other oncology compounds in clinical development, that that were discovered using in-house technology and have been shown to act as vascular disruption agents in solid tumors. EpiCept was founded in March 1993 and is headquartered in Tarrytown, NY. | 11 years |
Roger Aston | M | 68 | 7 years | |
Jeffrey D. Hillman | M | 75 | 15 years | |
Stefan Loren | M | 60 | 5 years | |
John P. Richard | M | 66 |
Targacept, Inc.
Targacept, Inc. Pharmaceuticals: OtherHealth Technology Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC. | 13 years |
Michael Valentino | M | 70 |
Adams Respiratory Therapeutics, Inc.
Adams Respiratory Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Adams Respiratory Therapeutics, Inc. manufactures over-the-counter remedies for respiratory ailments. The company's products include Mucinex, Mucinex DM, Maximum Strength Mucinex, Mucinex DM, Mucinex D, and the Delsym. It is a subsidiary of Reckitt Benckiser Corp. Adams Respiratory Therapeutics is headquartered in Chester, NJ | 5 years |
John N. Bonfiglio | M | 69 | 3 years | |
Wayne P. Yetter | M | 78 |
EpiCept Corp.
EpiCept Corp. Pharmaceuticals: MajorHealth Technology EpiCept Corp. is a pharmaceutical company, which focuses on the clinical development and commercialization of pharmaceutical products for the treatment of cancer and pain. The company focuses on analgesics targeting peripheral nerve receptors and cancer therapies. Its lead product Ceplene, is used concomitantly with low-dose interleukin-2, is intended as remission maintenance therapy in the treatment of acute myeloid leukemia for adult patients. The company's other oncology compounds include AmiKet, a late-stage pain product candidate for the treatment of peripheral neuropathies, and two other oncology compounds in clinical development, that that were discovered using in-house technology and have been shown to act as vascular disruption agents in solid tumors. EpiCept was founded in March 1993 and is headquartered in Tarrytown, NY. | 6 years |
Michael Denis Coffee | M | 77 | 3 years | |
Stephen Hill | M | 65 |
Targacept, Inc.
Targacept, Inc. Pharmaceuticals: OtherHealth Technology Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC. | 3 years |
Christine L. Koski | F | 66 | 7 years | |
Joseph Scodari | M | 71 | 9 years | |
Mark B. Skaletsky | M | 75 |
Targacept, Inc.
Targacept, Inc. Pharmaceuticals: OtherHealth Technology Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC. | 12 years |
Donald Williams | M | 65 | 5 years | |
Martin Handfield | M | 52 | 14 years | |
Glen Richards | M | - | 5 years | |
James Wilson | M | 80 |
Syntex Corp.
| 3 years |
Raymond Raphael Sackler | M | 79 |
Purdue Pharma LP
Purdue Pharma LP Pharmaceuticals: MajorHealth Technology Purdue Pharma LP engages in the development and provision of prescription medicines. It offers a portfolio of medical products in categories, including prescription opioids, sleep, laxatives, antiseptics, and dietary supplement. The company was founded by Raymond R. Sackler in 1991 and is headquartered in Stamford, CT. | 26 years |
David B. Hirsch | M | 55 | 3 years | |
Craig Landau | M | - |
Purdue Pharma LP
Purdue Pharma LP Pharmaceuticals: MajorHealth Technology Purdue Pharma LP engages in the development and provision of prescription medicines. It offers a portfolio of medical products in categories, including prescription opioids, sleep, laxatives, antiseptics, and dietary supplement. The company was founded by Raymond R. Sackler in 1991 and is headquartered in Stamford, CT. | - |
Robert E. Campbell | M | 90 | 36 years | |
Mark Timney | M | 58 |
Purdue Pharma LP
Purdue Pharma LP Pharmaceuticals: MajorHealth Technology Purdue Pharma LP engages in the development and provision of prescription medicines. It offers a portfolio of medical products in categories, including prescription opioids, sleep, laxatives, antiseptics, and dietary supplement. The company was founded by Raymond R. Sackler in 1991 and is headquartered in Stamford, CT. | 3 years |
John L. Armstrong | M | 80 | 7 years | |
Charles E. Darder | M | - |
EpiCept Corp.
EpiCept Corp. Pharmaceuticals: MajorHealth Technology EpiCept Corp. is a pharmaceutical company, which focuses on the clinical development and commercialization of pharmaceutical products for the treatment of cancer and pain. The company focuses on analgesics targeting peripheral nerve receptors and cancer therapies. Its lead product Ceplene, is used concomitantly with low-dose interleukin-2, is intended as remission maintenance therapy in the treatment of acute myeloid leukemia for adult patients. The company's other oncology compounds include AmiKet, a late-stage pain product candidate for the treatment of peripheral neuropathies, and two other oncology compounds in clinical development, that that were discovered using in-house technology and have been shown to act as vascular disruption agents in solid tumors. EpiCept was founded in March 1993 and is headquartered in Tarrytown, NY. | 6 years |
John Chiplin | M | 66 | 3 years | |
Philippe Calais | M | 65 | 1 years | |
Mehmood Khan | M | 66 | 3 years | |
Geoffrey O'Brien | M | 55 | 15 years | |
Hiroaki Shigeta | M | 81 | 6 years | |
Christine Poon | F | 71 | 9 years | |
James Cullen | M | 81 | 20 years | |
Leo Mullin | M | 81 | 16 years | |
James Karis | M | 76 | 3 years | |
Peter A. Zorn | M | 53 |
Targacept, Inc.
Targacept, Inc. Pharmaceuticals: OtherHealth Technology Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC. | 10 years |
Edward B. Mahony | M | - |
Purdue Pharma LP
Purdue Pharma LP Pharmaceuticals: MajorHealth Technology Purdue Pharma LP engages in the development and provision of prescription medicines. It offers a portfolio of medical products in categories, including prescription opioids, sleep, laxatives, antiseptics, and dietary supplement. The company was founded by Raymond R. Sackler in 1991 and is headquartered in Stamford, CT. | 25 years |
Errol de Souza | M | 70 |
Targacept, Inc.
Targacept, Inc. Pharmaceuticals: OtherHealth Technology Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC. | 11 years |
Geoffrey C. Dunbar | M | 77 |
Targacept, Inc.
Targacept, Inc. Pharmaceuticals: OtherHealth Technology Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC. | 11 years |
Gregory Sessler | M | 71 | 4 years | |
Jack L. Bowman | M | 91 | 7 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 90 | 90.00% |
Australia | 11 | 11.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Alan Dunton
- Personal Network